Since PD-1/PD-L1 interaction prevents the phagocytosis of tumor cells by macrophages, our hypothesis was to achieve an additional effect by inhibiting PD1/PD-L1 interaction acting on both genes in their respective cell lines, thus increasing the efficacy of the immunotherapeutic treatment. This evidence concerns the gene PDCD1 and neoplasm.